The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $15.56

Today's change+0.43 +2.84%
Updated May 6 10:48 AM -4GMT. Delayed by at least 15 minutes.
 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $15.56

Today's change+0.43 +2.84%
Updated May 6 10:48 AM -4GMT. Delayed by at least 15 minutes.

Osiris Therapeutics Inc up sharply

Osiris Therapeutics Inc is up sharply today, rallying (U.S.)$0.43 or 2.84% to (U.S.)$15.56. Shares have lost 0.51% over the last five days, but are unchanged over the last year to date. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $15.32
  • Previous close(U.S.) $15.13
  • High(U.S.) $15.68
  • Low(U.S.) $15.32
  • Bid / Ask(U.S.) $15.47 / (U.S.) $15.57
  • YTD % change-2.69%
  • Volume49,315
  • Average volume (10-day)121,866
  • Average volume (1-month)137,629
  • Average volume (3-month)143,739
  • 52-week range(U.S.) $11.87 to (U.S.) $18.86
  • Beta1.19
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward42.62×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.01
Updated May 6 10:48 AM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-0.41%

Osiris Therapeutics Inc has a net profit margin of -0.41%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX1.21%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue19171310
Total other revenue--------
Total revenue19171310
Gross profit1513108
Total cost of revenue4432
Total operating expense18161311
Selling / general / administrative101198
Research & development4111
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income110-1
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax11-1-1
Income after tax11-1-1
Income tax, total0000
Net income11-2-1
Total adjustments to net income--------
Net income before extra. items11-1-1
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items11-1-1
Inc. avail. to common incl. extra. items11-2-1
Diluted net income11-2-1
Dilution adjustment0----0
Diluted weighted average shares34353434
Diluted EPS excluding extraordinary itemsvalue per share0.030.02-0.04-0.02
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.030.02-0.04-0.02